Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC

Ping Chen,Yinfeng Li,Xiaomei Jing,Jing Chen, Shimei Chen,Qing Yang

Lung Cancer（2022）

引用 2|浏览19

暂无评分

摘要

•Combination chemotherapy with sugemalimab may be cost-effectiveness.•Cost of sugemalimab has a large impact on Markov model results.•Reshaping first-line treatment of lung cancer with sugemalimab in China.

查看译文

关键词

NSCLC,ICER,LY,QALY,WTP,EGFR,ALK,AEs,PFS,GDP,IPD,AIC,PSA

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要